On April 12, Novogene Co.Ltd(688315) ( Novogene Co.Ltd(688315) ) handed over its first report card after listing just one year after its listing (listed on April 13 last year).
In 2021, Novogene Co.Ltd(688315) achieved an operating revenue of 1.866 billion yuan, with a year-on-year increase of 25.26%; The net profit was 225 million yuan, a year-on-year increase of 515.74%.
Statistics show that Novogene Co.Ltd(688315) business covers basic scientific research services of life sciences, medical research and technology services, database building and sequencing platform services, and provides services such as gene sequencing, mass spectrometry analysis and bioinformation technology support for global research universities, scientific research institutes, hospitals, pharmaceutical R & D enterprises and agricultural enterprises.
There are four main reasons for the growth of Novogene Co.Ltd(688315) performance in 2021: first, comprehensively improve the capacity and scale of global sequencing services; Second, continuously innovate technology and solution system and expand the service boundary of multi omics; Third, strengthen intelligent, automatic production and information operation; Fourth, promote the coordinated development of multiple fields from basic research, transformation research to clinical application.
In terms of improving the capacity and scale of global sequencing services, Novogene Co.Ltd(688315) passed ISO / IEC 17025 (Cambridge experimental center, UK) in February last year; Tianjin experimental center and Singapore experimental center have completed the expansion of the third-generation sequencing platform; Last November, it officially became an officially certified sequencing service provider of pacbio.
In addition, Novogene Co.Ltd(688315) last year also launched preparations for new laboratories in Shanghai and other places. On March 23, Novogene Co.Ltd(688315) announced that it planned to issue shares to specific objects to raise funds, and planned to build or expand laboratories in more countries and regions to further implement the strategy of “global localization”.
In terms of strengthening intelligent, automatic production and information operation, last year Novogene Co.Ltd(688315) carried out intelligent transformation of traditional offline manual amplification sequencing; Complete the research and development of mass spectrometry pretreatment automatic production line, and expand the application of automatic production line to many omics business fields.
According to BCC research, the global gene sequencing market will reach US $10.7 billion in 2018 and is expected to maintain rapid growth in the next few years. It will reach US $24.4 billion in 2023, with a compound growth rate of 18% from 2018 to 2023; Among them, the market scale of gene sequencing services will increase from US $5.5 billion in 2018 to US $14 billion in 2023, with a compound growth rate of 20.4%.
Gene sequencing is a technology intensive industry. The main technologies include nucleic acid extraction, database construction, sequencing technology and Bioinformation Analysis Technology for data interpretation. The core technical barriers of the industry are high, the production process is complex, the technical mastery and innovation are difficult, and the quality control requirements are high. It is difficult for new entrants to master various technologies and form competitiveness in a short time.
In 2021, Novogene Co.Ltd(688315) continued to increase R & D investment, with a total R & D investment of 150 million yuan, a year-on-year increase of 33.91%. In terms of accumulation of scientific research achievements, Novogene Co.Ltd(688315) has published nearly 500 papers (more than 100 signed cooperative articles) in international journals in the past five years, and obtained 40 patents related to gene sequencing technology and 238 software copyrights.
